Immunotherapy with low-dose interleukin-2: Rationale for prevention of immune-deficiency-associated cancer

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Khatri, Vijay P ^a   Baiocchi, Robert A ^a   Bernstein, Zale P ^a   Caligiuri, Michael A ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Acquired immune deficiency syndrome; Cytokine; Epstein Barr virus; Immunodeficiency; Immunotherapy; Interleukin 2; Lymphoma; Lymphoproliferative disorders

Indexed keywords

INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; VIRUS CARCINOGENESIS; ANIMAL; B CELL LYMPHOMA; BLOOD; DISEASE MODEL; DRUG EFFECT; IMMUNOTHERAPY; LYMPHOCYTE TRANSFUSION; METHODOLOGY; MORTALITY; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SURVIVAL RATE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-6; LYMPHOCYTE TRANSFUSION; LYMPHOMA, AIDS-RELATED; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, SCID; SURVIVAL RATE;

EID: 0031406299     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Purtilo DT, Linder J. Oncological consequences of impaired immune surveillance against ubiquitous viruses. J Clin Immunol 1993;3:197-206.
2. Purtilo DT. Opportunistic cancers in patients with immunodeficiency syndromes [published erratum appears in Arch Pathol Lab Med 1988;112:234]. Arch Pathol Lab Med 1987;111:1123-1129.
3. Penn I. Tumors of the immunocompromised patient. Ann Rev Med 1988;39:63-73.
4. Tossing G. Immunodeficiency and its relation to lymphoid and other malignancies. Ann Hematol 1996;73:163-167.
5. Biemer JJ. Malignant lymphomas associated with immunodeficiency states. Ann Clin Lab Sci 1990;20:175-191.
6. Levine AM. Lymphoma in acquired immunodeficiency syndrome. Semin Oncol 1990;17:104-112.
7. Bernstein ZP, Porter MM, Gould M et al. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995; 86:3287-3294.
8. Gill PS, Lunardi-Iskandar Y, Louie S et al. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma [published erratum appears in N Engl J Med 1997; 336:670]. N Engl J Med 1996;335:1261-1269.
9. Abbas AK, Williams ME, Burstein HJ et al. Activation and functions of CD4+ T-cell subsets. Immunol Rev 1991;123:5-22.
10. Hsieh CS, Macatonia SE, Tripp CS et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-549.
11. Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol 1995;15:121-129.
12. O'Garra A, Murphy K. Role of cytokines in development of Th1 and Th2 cells. Chem Immunol 1996;63:1-13.
13. Hsieh CS, Heimberger AB, Gold JS et al. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc Natl Acad Sci U S A 1992;89:6065-6069.
14. Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996;80:225-235.
15. Filipovich AH, Mathur A, Kamat D et al. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency 1994;5:91-112.
16. Stasi R, Zinzani L, Galieni P et al. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol 1995;54:9-17.
17. Benjamin D, Knobloch TJ, Dayton MA Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 1992;80:1289-1298.
18. Karp JE, Broder S. Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas. Cancer Res 1991;51:4743-4756.
19. Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood 1992;80:8-20.
20. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527-530.
21. Mosier DE. Adoptive transfer of human lymphoid cells to severely immunodeficient mice: models for normal human immune function, autoimmunity, lymphomagenesis, and AIDS. Adv Immunol 1991;50:303-325.
22. Rowe M, Young LS, Crocker J et al. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991;173:147-158.
23. Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Ann Rev Med 1995;46:381-394.
24. Picchio GR, Kobayashi R, Kirven M et al. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. Cancer Res 1992;52:2468-2477.
25. Veronese ML, Veronesi A, D'Andrea E et al. Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice: T lymphocyte requirement for B cell tumor generation [part 1]. J Exp Med 1992; 176:1763-1767.
26. Rickinson AB, Lee SP, Steven NM. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 1996;8:492-497.
27. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993;262:1011-1018.
28. Graziosi C, Pantaleo G, Gantt KR et al. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 1994;265:248-252.
29. Rickinson AB: Cellular immunology responses to the virus infection. In: Epstein MA, Achong BG, eds. The Epstein-Barr Virus, Recent Advances. New York: Wiley Medical Publications, 1990;75.
30. Shibata D, Weiss LM, Hernandez AM et al. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood 1993;81:2102-2109.
31. Baiocchi RA, Caligiuri MA. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in SCID/SCID mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci U S A 1994;91:5577-5581.
32. Khatri W, Baiocchi RA, Bernstein ZP et al. Lymphomagenesis in the severe combined immune deficient mouse engrafted with human lymphocytes: clues towards me pathogenesis and treatment of AIDS lymphoma (review). Oncol Rep 1997;4:241-246.
33. Hill AB, Lee SP, Haurum JS et al. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med 1995;181:2221-2228.
34. Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today 1992;13:198-200.
35. Tosato G, Tanner J, Jones KD et al. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 1990;64:3033-3041.
36. Baiocchi RA, Ross ME, Tan JC et al. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood 1995;85:1063-1074.
37. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell: Th2 clones secrete a factor that inhibits cytokine production by Th1 clones [part 4]. J Exp Med 1989;170:2081-2095.
38. D'Andrea A, Aste-Amezaga M, Valiante NM et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041-1048.
39. Peters BS, Beck EJ, Coleman DG et al. Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. BMJ 1991;302:203-207.
40. Knowles DM, Chadburn A: Lymphadenopathy and the lymphoid neoplasms associated with the acquired immune deficiency syndrome (AIDS). In: Knowles DM, ed. Neoplastic Hematopathology. Baltimore: Williams & Wilkins, 1992;773.
41. Meeker TC, Shiramizu B, Kaplan L et al. Evidence for molecular subtypes of HIV-associated lymphoma: division into peripheral monoclonal, polyclonal and central nervous system lymphoma. AIDS 1991;5:669-674.
42. Levine AM, Shibata D, Sullivan-Halley J et al. Case control study of HIV-positive and HIV-negative lymphoma in Los Angeles County. Proceedings of ASCO 1992;11:333.
43. MacMahon EM, Glass JD, Hayward SD et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991;338:969-973.
44. Murray HW, Weite K, Jacobs JL et al. Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome. J Clin Invest 1985;76:1959-1964.
45. Lewis DE, Tang DS, Adu-Oppong A et al. Anergy and apoptosis in CD8+ T cells from HIV-infected persons. J Immunol 1994; 153:412-420.
46. Meyaard L, Otto SA, Jonker RR et al. Programmed death of T cells in HIV-1 infection. Science 1992;257:217-219.
47. Clerici M, Sarin A, Coffman RL et al. Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci U S A 1994;91:11811-11815.
48. Rook AH, Hooks JJ, Quinnan GV et al. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism. J Immunol 1985;134:1503-1507.
49. Caligiuri MA, Zmuidzinas A, Manley TJ et al. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes: identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990;171:1509-1526.
50. Nagler A, Lanier LL, Phillips JH. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J Exp Med 1990;171:1527-1533.
51. Carson WE, Fehniger TA, Caligiuri MA. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol 1997;27:354-360.
52. Bluman EM, Bartynski KJ, Avalos BR et al. Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines. J Clin Invest 1996;97:2722-2727.
53. Khatri VP, Yu F, Baiocchi RA et al. Analysis of TH1/TH2 cytokine gene profile during low-dose IL-2 therapy in patients with AIDS or AIDS lymphoma. J Acquir Immune Defic Syndr Human Retrovirol 1997;14:A41.
54. Walker BD. The rationale for immunotherapy in HIV-1 infection. J Acquir Immune Defic Syndr 1994;7[suppl 1]:S6-S13.